What is Canid?
Canid is fundamentally transforming the pediatric vaccine management landscape by replacing antiquated, manual processes with a sophisticated, AI-integrated platform. The company's core value proposition lies in its ability to interface seamlessly with existing electronic health record (EHR) systems, effectively automating the complex documentation and inventory management tasks that currently plague pediatricians. By leveraging economies of scale and advanced software architecture, Canid reduces the time and financial overhead required for vaccine administration, allowing healthcare providers to focus on patient care rather than administrative compliance.
In a market where clinical burnout is at an all-time high, Canid's solution serves as a vital tool for operational efficiency. The platform's design philosophy centers on simplicity and speed, ensuring that the transition to digital-first vaccine management is frictionless for medical staff. As the company continues to refine its AI capabilities, it is poised to become an indispensable component of the pediatric healthcare technology stack.
How much funding has Canid raised?
Canid has raised a total of $12.5M across 3 funding rounds:
Angel/Pre-Seed
$1M
Seed
$1.5M
Series A
$10M
Angel/Pre-Seed (2021): $1M, investors not publicly disclosed
Seed (2023): $1.5M led by FJ Labs and Alumni Ventures
Series A (2025): $10M supported by FJ Labs, Brooklyn Bridge Ventures, SeedtoB Capital, and Telescope Partners
Key Investors in Canid
FJ Labs
FJ Labs specializes in venture-scale angel investing, focusing on marketplaces and network effect businesses with a portfolio that includes over 30 unicorn companies.
SeedtoB Capital
SeedtoB Capital is an investment firm dedicated to supporting healthcare AI startups, leveraging deep industry expertise to guide companies from early stages toward Series B maturity.
Telescope Partners
Telescope Partners is a thesis-driven, early-growth investor that provides high-touch, bespoke support to entrepreneurs building exceptional enterprise software companies.
What's next for Canid?
With the successful closure of this major strategic investment, Canid is well-positioned to accelerate its market penetration and enhance its product suite. The capital will likely be deployed toward expanding the company's engineering team to further refine its AI-driven EHR integration capabilities and scaling its sales operations to reach a broader network of pediatric clinics. Furthermore, the strategic backing from specialized healthcare and enterprise software investors suggests a focus on long-term sustainability and potential expansion into adjacent clinical workflows.
As Canid moves into this next phase of growth, the focus will shift toward establishing deeper partnerships with large-scale healthcare networks and health systems. By proving the efficacy of its scan-and-go workflow at scale, the company aims to set a new industry standard for vaccine management, ultimately driving better health outcomes through technological innovation and operational excellence.
